Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
0.00 | 0.00 | 2.35B | 22.98M | 1.40B | 2.10B | Gross Profit |
-33.35M | -44.35M | 2.30B | 22.98M | 1.40B | 2.10B | EBIT |
-2.16B | -2.08B | 142.39M | -1.98B | -593.73M | 415.71M | EBITDA |
-2.10B | -2.03B | 218.05M | -1.90B | -532.23M | 369.06M | Net Income Common Stockholders |
-2.12B | -2.02B | 168.35M | -1.95B | -582.45M | 347.76M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
8.02B | 8.41B | 10.22B | 8.88B | 10.17B | 10.68B | Total Assets |
8.67B | 9.08B | 10.71B | 9.60B | 10.91B | 11.28B | Total Debt |
0.00 | 0.00 | 531.00K | 3.67M | 6.73M | 9.71M | Net Debt |
-8.02B | -8.41B | -10.22B | -8.88B | -10.17B | -10.67B | Total Liabilities |
273.69M | 185.88M | 336.02M | 192.43M | 212.64M | 431.36M | Stockholders Equity |
8.40B | 8.89B | 10.37B | 9.40B | 10.70B | 10.85B |
Cash Flow | Free Cash Flow | ||||
0.00 | -1.88B | 1.13B | -1.40B | -609.23M | 422.44M | Operating Cash Flow |
0.00 | -1.88B | 1.14B | -1.40B | -519.65M | 575.41M | Investing Cash Flow |
0.00 | -4.78M | -344.00K | -330.00K | -92.72M | -153.71M | Financing Cash Flow |
0.00 | 78.97M | 202.60M | 112.86M | 109.32M | 7.76B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $1.30T | 25.47 | 6.04% | 2.33% | 8.90% | -37.00% | |
71 Outperform | $2.49T | 48.68 | 3.22% | 5.36% | 19.25% | 294.48% | |
70 Neutral | ¥1.14T | 24.63 | 5.34% | 3.97% | 6.42% | 10.82% | |
67 Neutral | $6.44T | 22.15 | 17.60% | 1.74% | 17.77% | 48.97% | |
65 Neutral | $6.89T | 63.56 | 1.50% | 4.52% | 7.45% | -25.77% | |
54 Neutral | $5.24B | 3.26 | -44.35% | 6.48% | 16.78% | -0.10% | |
47 Neutral | ¥20.94B | ― | ― | -100.00% | -1079.89% |
StemRIM Inc. has announced the setting of a record date for an Extraordinary General Meeting of Shareholders and a capital stock reduction. The capital reduction aims to enhance financial flexibility and reduce tax burdens without affecting the company’s net assets or shareholders’ equity. This strategic financial maneuver is expected to streamline StemRIM’s capital policies, subject to shareholder approval, and reflects the company’s commitment to maintaining operational efficiency.
StemRIM Inc. has secured a patent in China for its peptide drug Redasemtide, aimed at treating traumatic articular cartilage deficiency syndrome, osteoarthritis, and osteochondritis dissecans. This patent is expected to enhance the development potential of Redasemtide in China, a rapidly growing pharmaceutical market, and support the global expansion of StemRIM’s ‘Regeneration-Inducing Medicine™’. While the immediate financial impact is minimal, the patent positions StemRIM strategically in the global biotech industry.
StemRIM Inc. announced the interim analysis results of its global Phase 2b clinical trial for Redasemtide, a treatment for acute ischemic stroke, conducted in collaboration with Shionogi & Co., Ltd. The trial, which spans 18 countries, aims to evaluate Redasemtide’s efficacy in patients not eligible for endovascular recanalization therapy. The interim analysis recommended continuing the trial for the 1.5 mg/kg dose group while discontinuing the 0.75 mg/kg group, aligning with initial expectations and potentially reducing the required number of subjects. This development is significant for the clinical advancement of Redasemtide, although it currently has no impact on StemRIM’s financial results for the fiscal year ending July 31, 2025.
StemRIM Inc. reported a net loss for the six months ending January 31, 2025, with no operating revenue recorded. The company’s financial position showed a decrease in total assets and net assets compared to the previous period. Despite the financial challenges, StemRIM remains committed to its R&D efforts, with significant cash outflows expected for research and development through 2028. The company has not provided a financial forecast for the fiscal year ending July 31, 2025, due to the unpredictable nature of milestone revenues from development partnerships.
StemRIM Inc. announced a protocol amendment for its global Phase 2b clinical trial of Redasemtide, a treatment for acute ischemic stroke, which is being conducted in collaboration with Shionogi & Co., Ltd. The amendment includes adding a new cohort of patients who have undergone endovascular recanalization therapy and relaxing eligibility criteria, allowing broader patient participation without significantly extending the trial period. This adjustment is crucial as the market for ischemic stroke treatments is expected to reach $10.56 billion by 2027, and the changes aim to adapt to the evolving treatment landscape.